Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Life Sci. 2020 Oct 15;259:118379. doi: 10.1016/j.lfs.2020.118379. Epub 2020 Sep 3.
With the increasing application of medical imaging contrast materials, contrast-induced nephropathy has become one of the leading causes of iatrogenic renal insufficiency. The underlying mechanism is associated with renal medullary hypoxia, direct toxicity of contrast agents, oxidative stress, apoptosis, immune/inflammation and epigenetic regulation in contrast-induced nephropathy. Up to date, there is no effective therapy for contrast-induced nephropathy, and thus risk predication and effective preventive strategies are keys to reduce the occurrence of contrast-induced nephropathy. It was found that the proper use of contrast medium, personalized hydration, and high-dose statins may reduce the occurrence of contrast-induced nephropathy, while antioxidants have not shown significant therapeutic benefits. Additionally, the role of remote ischemia preconditioning and vasodilators in the prevention of contrast-induced nephropathy needs further study. This review aims to discuss the incidence, pathogenesis, risk prediction, and preventive strategies for contrast-induced nephropathy.
随着医学影像学对比剂的应用日益增多,对比剂肾病已成为医源性肾功能不全的主要原因之一。其发病机制与肾髓质缺氧、对比剂直接毒性、氧化应激、细胞凋亡、免疫/炎症及表观遗传调控有关。目前,对比剂肾病尚无有效的治疗方法,因此预测风险和采取有效的预防策略是降低对比剂肾病发生的关键。现已发现,合理使用对比剂、个体化水化、大剂量他汀类药物可能减少对比剂肾病的发生,而抗氧化剂并未显示出显著的治疗益处。此外,远程缺血预处理和血管扩张剂在预防对比剂肾病中的作用尚需进一步研究。本文旨在探讨对比剂肾病的发生率、发病机制、风险预测和预防策略。